# Pet Medtech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pet-medtech

- Industry: Pharmaceuticals
- Headquarters: Nanjing, China
- Website: www.petmedtech.com
- Latest round: Series A (Jul 10, 2026)
- Investors on record: 3

## About

Based in Nanjing, China and founded in 2023, Nanjing PetMedTech Co., Ltd., trading as Pet Medtech, is an innovative pet drug developer, primarily engaged in the prevention, diagnosis, treatment, and healthcare of animal diseases, as well as veterinary drug production and distribution. The company has been awarded the title of National High-tech Enterprise. In July 2026, it raised tens of millions of CNY in series A funding. Pet Medtech focuses on innovative pet drugs and high-end formulation platforms, combining imitation and innovation to address the current shortage of veterinary drugs and medications in the pet treatment field. It is committed to building a one-stop innovative technology service platform for pet health, with products covering the prevention, diagnosis, treatment, and health maintenance of pet diseases. The company’s revenue is generated from the sale of pet medicines and pet disease treatment services. The company will use the latest funding to strengthen its strategic layout in the research and development pipeline and market expansion of innovative pet drugs. It will continue to integrate AI to deeply develop its R&D pipeline so as to bring original Chinese-developed pet drugs to the global market as soon as possible.

## Funding rounds

- Series A, Jul 10, 2026 — CITIC Agriculture, Nanjing Future Pet Industry Research Institute Co., Ltd.
- Series A, Feb 5, 2026 — Triwise Capital

## Investors

- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series A
- CITIC Agriculture (https://capitalatlas.ai/funds/citic-agriculture) — Series A
- Nanjing Future Pet Industry Research Institute Co., Ltd. — Series A